Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MMM stock price vs REGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REGN's multiple
Needs REGN P/E.
Implied fair value · at MMM's multiple
Needs MMM P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
3M COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
REGENERON PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HONEYWELL INTERNATIONAL INC
MMM vs HON
DANAHER CORP /DE/
MMM vs DHR
Johnson & Johnson
MMM vs JNJ
EMERSON ELECTRIC CO
MMM vs EMR
AMGEN INC
MMM vs AMGN
PFIZER INC
MMM vs PFE
BRISTOL MYERS SQUIBB CO
MMM vs BMY
BIOGEN INC.
MMM vs BIIB
GILEAD SCIENCES, INC.
MMM vs GILD
Seagate Technology Holdings plc
MMM vs STX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MMM can sustain its current valuation despite only modest growth and higher leverage, then hold or avoid adding because the P/E-based framework implies meaningful downside and MMM trades above the DCF range.
MMM’s current price of $180.71 sits well above REGN-implied value of $111.68, implying -38.2% downside. The stock is also above the top end of REGN implied range and near the upper end of its historical band, while the DCF range is far below the market price.
Supporting Metrics
